Can You Take Abemaciclib and Ritonavir Together?

According to the FDA drug label for ritonavir, abemaciclib and ritonavir are marked as contraindicated—meaning the combination is not recommended and should be avoided. If you are taking or considering both medications, you need to discuss this with your pharmacist or physician before starting, continuing, or stopping either drug.

What the Source Says

The source of this information is the FDA-approved drug label for ritonavir, which lists abemaciclib among anticancer agents that interact with this HIV protease inhibitor. The label categorizes this combination as contraindicated rather than merely cautionable or manageable.

The FDA label describes the interaction this way: anticancer agents including abemaciclib show increased levels (↑) when combined with ritonavir, while ritonavir levels decrease (↓). The label does not specify a detailed mechanism for this particular pair but places abemaciclib in a group of anticancer drugs with documented interactions involving ritonavir.

The FDA notes that similar concerns about loss of virologic response and possible resistance to ritonavir or to the entire class of protease inhibitors can occur with certain drug combinations. This is why the interaction is flagged at the contraindicated level—the risk is considered serious enough to warrant avoidance.

How to Understand This

A contraindicated rating is the most serious category of drug interaction. It does not necessarily mean that taking the drugs together will cause immediate harm to every person, but it means the FDA has determined that the documented or theoretical risks are substantial enough that the combination should not be used under ordinary circumstances. Contraindicated status reflects a judgment that safer alternatives or different treatment approaches should be explored first.

In this case, the interaction involves changes to how your body processes both drugs:

• Abemaciclib levels go up. When ritonavir is present, your body may not clear abemaciclib as efficiently, leading to higher concentrations of the cancer drug in your blood. This increases the risk of abemaciclib side effects.
• Ritonavir levels go down. Abemaciclib may enhance the breakdown or clearance of ritonavir, reducing the amount of HIV protease inhibitor in your system. This raises concern about losing control of HIV viral replication.

The FDA label notes that loss of virologic response—meaning HIV becomes harder to control—and development of resistance to ritonavir or other protease inhibitors is a potential concern. These are significant risks for people with HIV who depend on consistent, effective antiretroviral therapy.

The source record does not specify the exact mechanism (for example, whether this involves shared metabolic pathways, enzyme induction, or transporter competition). However, both abemaciclib and ritonavir undergo processing in the liver, and both can affect how other drugs are metabolized. General pharmacology suggests that when two drugs interact with the same metabolic system, altered levels of one or both are common. That background context is well established, but the specific bidirectional effect documented here for this pair is drawn from the FDA label.

Who Should Pay Particular Attention

This contraindication applies broadly. However, certain situations make the interaction especially critical to address:

• If you have HIV and are taking ritonavir-based antiretroviral therapy: Any reduction in ritonavir levels or switch in viral control is a serious clinical concern. Your HIV regimen is designed to maintain consistent suppression, and a documented interaction that lowers ritonavir levels creates real risk.
• If you are on abemaciclib for breast cancer or another indication: Unplanned increases in abemaciclib concentration can amplify side effects such as diarrhea, infection risk, or liver toxicity—effects that can be difficult to manage.
• If you are newly diagnosed with both conditions or require a treatment change: The time to address this is before starting a medication, not after side effects emerge or viral resistance develops.

More broadly, this interaction highlights why it is essential to keep a complete, up-to-date medication list and to share it with every healthcare provider involved in your care—including your oncologist, infectious disease specialist or primary care physician, and pharmacist.

Hypothetical Examples

Scenario 1 (Hypothetical): A patient with HIV on a stable ritonavir-based regimen is diagnosed with hormone-receptor–positive breast cancer and a physician proposes abemaciclib. Before filling the abemaciclib prescription, the pharmacist checks for interactions and flags the contraindication. The medical team then discusses alternative anticancer drugs that do not interact with ritonavir, or re-evaluates the HIV regimen to see if a non-protease-inhibitor–based approach might work. This is the ideal outcome: the interaction is caught early, and a safe plan is made.

Scenario 2 (Hypothetical): A patient has been taking abemaciclib and then later starts ritonavir as part of a new HIV regimen. The interaction may not be immediately obvious if the patient sees different specialists and the medication lists are not coordinated. Over weeks, the patient might experience worsening diarrhea and fatigue (abemaciclib toxicity signals) or changes in viral load (ritonavir effectiveness signal). Investigation then reveals that the two drugs should not have been combined, and urgent re-planning is needed. This scenario illustrates why proactive communication among all care providers is essential.

What to Discuss With a Pharmacist or Physician

If you are taking or considering both abemaciclib and ritonavir, or if you are on one and your doctor proposes the other, these are important questions to ask:

• "I see this combination is flagged as contraindicated. What are the specific risks for my situation, and why is this combination being considered despite that flag?" A contraindicated status does not automatically mean the drugs cannot be used together in unusual circumstances, but your doctor should explain the clinical reasoning if they are proposing it anyway.
• "Are there alternative anticancer drugs that do not interact with ritonavir?" If you have HIV, this question is particularly important. Your oncologist and infectious disease specialist should collaborate to find a cancer treatment that does not compromise your HIV regimen.
• "Are there alternative HIV regimens that do not include ritonavir?" Similarly, if you have cancer and require abemaciclib, it may be possible to switch to an HIV regimen based on other protease inhibitors or other drug classes that do not interact with abemaciclib.
• "If I am already on both, what should we monitor, and what are the warning signs I should watch for?" If the combination is already in place (perhaps because it was not caught as an interaction earlier), ask about monitoring: blood tests for viral load and CD4 count (HIV control), liver and kidney function (drug clearance), and symptoms of abemaciclib toxicity (severe diarrhea, infection, bleeding, bruising).
• "Should I contact my pharmacist before starting, stopping, or changing the dose of either medication?" Timing matters. If one drug is stopped, the levels of the other may shift significantly, requiring dose adjustments or close follow-up.

Do not stop or change either medication on your own. A sudden stop can have serious consequences for HIV control or cancer treatment. Instead, bring the FDA interaction alert to your appointment and ask your team to review it together. If your doctors have decided to use the combination despite the contraindication, ask them to document the clinical reasoning and to explain how they will monitor for problems.

Key Takeaways

• Abemaciclib and ritonavir are listed as contraindicated by the FDA, meaning the combination should be avoided under standard circumstances.
• The interaction involves increased abemaciclib levels and decreased ritonavir levels, raising concerns about abemaciclib toxicity and loss of HIV viral control.
• The FDA label does not specify a detailed mechanism for this pair, but both drugs are processed in the liver and can affect how other medications are metabolized.
• If you take or are considering both medications, discuss this contraindication with your pharmacist and all your doctors before starting, stopping, or changing either drug.
• Alternative anticancer drugs or alternative HIV regimens may be available and should be explored to avoid this interaction.

Sources

This article is based on the FDA-approved drug label for ritonavir. For the complete label and other official drug information:

• DailyMed (National Library of Medicine) — Search "ritonavir" to view the current FDA label and all listed interactions.
• FDA Open Data — Official FDA drug information repository.
• RxNorm (National Library of Medicine) — Standardized drug nomenclature and related identifiers.
• PubMed (National Library of Medicine) — Peer-reviewed biomedical literature for in-depth background on drug interactions and HIV protease inhibitors.

Next Steps

If you are taking abemaciclib, ritonavir, or both, your next step is to check your complete medication list at checkdruginteractions.com. This tool will flag documented interactions and help you and your healthcare team identify potential concerns. Always confirm any medication decisions—including whether to start, continue, adjust, or stop a drug—with your pharmacist or physician. If you have been taking both drugs without knowing about this interaction, schedule an urgent review with your care team. Your safety depends on clear communication across all your providers.